• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间变性淋巴瘤激酶阳性非小细胞肺癌IV期挽救性手术后迟发性支气管胸膜瘘的形成

Delayed Bronchopleural Fistula Formation Following Salvage Surgery of Stage IV Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

作者信息

Barter Lauren, Snow Stephanie, Mujoomdar Aneil, Best Lara, French Daniel

机构信息

Faculty of Medicine, Carleton Campus, Dalhousie University, 5849 University Ave., Halifax, NS B3H 4R2, Canada.

Division of Medical Oncology, Department of Internal Medicine, Halifax, NS B3H 2Y9, Canada.

出版信息

Curr Oncol. 2025 Apr 25;32(5):250. doi: 10.3390/curroncol32050250.

DOI:10.3390/curroncol32050250
PMID:40422509
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12110444/
Abstract

This case report highlights the management of a delayed bronchopleural fistula (BPF) following salvage pulmonary resection to achieve local control and no radiographic evidence of disease in a patient treated with serial tyrosine kinase inhibitors (TKIs) for stage IV anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). The initial pulmonary resection was complicated by dense adhesions and an abnormally torturous pulmonary artery. Six weeks after the index surgery, the patient presented with a delayed BPF requiring decortication, repair of airway, and coverage of the bronchial stump with a serratus anterior muscle flap.

摘要

本病例报告强调了在一名接受序贯酪氨酸激酶抑制剂(TKIs)治疗的IV期间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌(NSCLC)患者中,为实现局部控制且影像学无疾病证据而进行挽救性肺切除术后延迟性支气管胸膜瘘(BPF)的处理。初次肺切除因致密粘连和异常迂曲的肺动脉而复杂化。初次手术后六周,患者出现延迟性BPF,需要进行胸膜剥脱术、气道修复以及用前锯肌瓣覆盖支气管残端。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/4d0b324cea61/curroncol-32-00250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/7b8437135d12/curroncol-32-00250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/794653883bfe/curroncol-32-00250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/4d0b324cea61/curroncol-32-00250-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/7b8437135d12/curroncol-32-00250-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/794653883bfe/curroncol-32-00250-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/440c/12110444/4d0b324cea61/curroncol-32-00250-g003.jpg

相似文献

1
Delayed Bronchopleural Fistula Formation Following Salvage Surgery of Stage IV Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.间变性淋巴瘤激酶阳性非小细胞肺癌IV期挽救性手术后迟发性支气管胸膜瘘的形成
Curr Oncol. 2025 Apr 25;32(5):250. doi: 10.3390/curroncol32050250.
2
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶(<I>ALK</I>)重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
3
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
4
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKI)作为一线治疗ALK 阳性晚期非小细胞肺癌(NSCLC)的比较:系统评价和网络荟萃分析。
Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.
5
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性:系统评价和网络荟萃分析。
Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.
6
Surgery for early stage non-small cell lung cancer.早期非小细胞肺癌的手术治疗
Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD004699. doi: 10.1002/14651858.CD004699.pub2.
7
A systematic overview of chemotherapy effects in non-small cell lung cancer.非小细胞肺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):327-39. doi: 10.1080/02841860151116402.
8
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.比较伴有 ALK 重排的晚期非小细胞肺癌一线治疗的疗效和安全性:临床试验的荟萃分析。
BMC Cancer. 2021 Nov 26;21(1):1278. doi: 10.1186/s12885-021-08977-0.
9
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗非小细胞肺癌患者的毒性特征:系统评价和荟萃分析。
Invest New Drugs. 2022 Aug;40(4):831-840. doi: 10.1007/s10637-022-01242-6. Epub 2022 Apr 18.
10
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.比较间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗间变性淋巴瘤激酶突变型晚期非小细胞肺癌的安全性:系统评价和网络荟萃分析。
Lung Cancer. 2023 Oct;184:107319. doi: 10.1016/j.lungcan.2023.107319. Epub 2023 Aug 7.

本文引用的文献

1
Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report.序贯表皮生长因子受体酪氨酸激酶抑制剂诱导的寡转移非小细胞肺癌根治性手术:1 例报告。
Oncologist. 2024 Jun 3;29(6):543-545. doi: 10.1093/oncolo/oyad339.
2
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.布加替尼对比阿来替尼用于克唑替尼治疗后进展的 ALK 阳性 NSCLC :III 期 ALTA-3 试验结果。
J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12.
3
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study.
先前免疫治疗后晚期非小细胞肺癌的挽救性手术:一项回顾性研究。
J Cardiothorac Surg. 2023 Jul 20;18(1):235. doi: 10.1186/s13019-023-02310-5.
4
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.真实世界中晚期ALK 重排非小细胞肺癌患者的治疗序贯、毒性、健康效用和生存结局。
Clin Lung Cancer. 2023 Jan;24(1):40-50. doi: 10.1016/j.cllc.2022.09.007. Epub 2022 Sep 24.
5
Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer.免疫疗法/酪氨酸激酶抑制剂治疗初始不可切除肺癌后的挽救性手术
Cancers (Basel). 2022 May 27;14(11):2661. doi: 10.3390/cancers14112661.
6
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)抑制剂:耐药机制与处理
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.
7
Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements.携带ALK重排的转移性非小细胞肺癌患者寡进展的管理
Cancers (Basel). 2022 Jan 30;14(3):718. doi: 10.3390/cancers14030718.
8
Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer.晚期非小细胞肺癌免疫化疗放疗后的挽救性手术
Surg Case Rep. 2022 Jan 21;8(1):17. doi: 10.1186/s40792-022-01371-3.
9
Salvage pulmonary resection in stages IIIb-IV lung cancer after treatment with immune checkpoint inhibitors case series and literature review.免疫检查点抑制剂治疗后 IIIb-IV 期肺癌分阶段挽救性肺切除术:病例系列和文献复习。
J Surg Oncol. 2022 Feb;125(2):290-298. doi: 10.1002/jso.26691. Epub 2021 Sep 27.
10
Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.靶向治疗使晚期非小细胞肺癌降期后的挽救性手术。
Thorac Cancer. 2021 Aug;12(15):2161-2169. doi: 10.1111/1759-7714.14044. Epub 2021 Jun 15.